Skip to content
The People's CodeSearch
Menu

Changes to the Code

H.R. 5526 · Biosimilar Red Tape Elimination Act ·

In committee · step 2 of 5

Sections are cited like “7 U.S.C. § 2012”: 7 of the , 2012.

42 U.S.C. § 262 Regulation of biological products

+41 −499 of 16 shown
More for 42 U.S.C. § 262
Read § 262Only this section
16 changes the bill asks for here, 9 carried out
  1. Carried out:

    in the subsection heading, by striking or interchangeable;

  2. Carried out:

    by striking subparagraph (B);

  3. Not carried out:

    by redesignating clauses (ii) and (iii) of subparagraph (A) as subparagraphs (B) and (C), respectively, and adjusting the margins accordingly;

    We can't read how this instruction is worded yet, so it isn't shown in the text.

    Technical detailno-pattern: redesignating clauses (X) and (X) of subparagraph (X) as subparagraphs (X) and (X), respectively, and adjusting the margins accordingly;
  4. Carried out:

    in clause (i), by redesignating subclauses (I) through (V) as clauses (i) through (v), respectively, and adjusting the margins accordingly;

  5. Carried out:

    in clause (i), as so redesignated by clause (i) of this subparagraph, by redesignating items (aa) through (cc) as subclauses (I) through (III), respectively, and adjusting the margins accordingly;

  6. Not carried out:

    in subclause (II) of clause (i), as so redesignated by clause (ii) of this subparagraph, by striking item (aa) or (cc) and inserting subclause (I) or (III); and

    “item (aa) or (cc)” isn't in § 262(k)(2)(A)(iii)(II) in the Code as we have it. The law may have changed since the bill was drafted.

    Technical detail“item (aa) or (cc)” not found in /us/usc/t42/s262/k/2/A/iii/II
  7. Not carried out:

    by striking (A) In General and all that follows through An application submitted under this subsection shall include information and inserting the following:(A) In general.— An application submitted under this subsection shall include information;

    We can't read how this instruction is worded yet, so it isn't shown in the text.

    Technical detailno-pattern: striking QTEXT and all that follows through QTEXT and inserting the following: QCONTENT;
  8. Not carried out:

    in subparagraph (B), as so redesignated by subparagraph (B) of this paragraph, by striking clause (i)(I) and inserting subparagraph (A)(i); and

    The bill points to subparagraph (B) of § 262(k)(2), which isn't there in the Code as we have it. It may have been renumbered or removed since the bill was drafted.

    Technical detailtarget not found: no subparagraph (B) in /us/usc/t42/s262/k/2
  9. Not carried out:

    in subparagraph (C), as so redesignated by subparagraph (B) of this paragraph, by redesignating subclauses (I) through (III) as clauses (i) through (iii), respectively, and by adjusting the margins accordingly;

    The bill points to subparagraph (C) of § 262(k)(2), which isn't there in the Code as we have it. It may have been renumbered or removed since the bill was drafted.

    Technical detailtarget not found: no subparagraph (C) in /us/usc/t42/s262/k/2
  10. Not carried out:

    by amending subparagraph (A) of paragraph (3) to read as follows:(A) the Secretary determines that the information submitted in the application (or the supplement) is sufficient to show that the biological product is biosimilar to the reference product; and;

    We can't read how this instruction is worded yet, so it isn't shown in the text.

    Technical detailno-pattern: amending subparagraph (X) of paragraph (X) to read as follows: QCONTENT;
  11. Carried out:

    by amending paragraph (4) to read as follows:(4) Interchangeability.— (A) In general.— A biological product licensed under this subsection shall be deemed to be interchangeable with the reference product, subject to subparagraph (B). (B) Timing of deemed interchangeability.— (i) Licensure on or after transition date.— A …

  12. Carried out:

    by amending paragraph (6) to read as follows:(6) Transition with respect to preserving first interchangeable exclusivity with respect to certain biological products.— With respect to a biological product licensed under this subsection before the date of enactment of the Biosimilar Red Tape Elimination Act, for which there …

  13. Carried out:

    in clause (i), by striking class; and and inserting class.;

  14. Carried out:

    by striking clause (ii); and

  15. Not carried out:

    by striking description of— and all that follows through criteria that the Secretary and inserting description of the criteria that the Secretary.

    The bill strikes from “description of—” through “criteria that the Secretary” in § 262(k)(8)(D), but “criteria that the Secretary” doesn't come after “description of—” there.

    Technical detail“criteria that the Secretary” does not follow “description of—” in /us/usc/t42/s262/k/8/D
  16. Carried out:

    Section 351(i)(3) of the Public Health Service Act (42 U.S.C. 262(i)(3)) is amended by striking that is shown to meet the standards described in subsection (k)(4) and inserting licensed under subsection (k).

§ 262(i)–(k)

Start of § 262 to (i)(2)(A) unchanged ·

(B) there are no clinically meaningful differences between the biological product and the reference product in terms of the safety, purity, and potency of the product.

(3) The term “interchangeable” or “interchangeability”, in reference to a biological product [struck: that][inserted: licensed] [struck: is][inserted: under] [struck: shown to meet the standards described in ]subsection (k)[struck: (4)], means that the biological product may be substituted for the reference product without the intervention of the health care provider who prescribed the reference product.

(4) The term “reference product” means the single biological product licensed under subsection (a) against which a biological product is evaluated in an application submitted under subsection (k).

(j) Application of Federal Food, Drug, and Cosmetic Act The Federal Food, Drug, and Cosmetic Act [21 U.S.C. 301 et seq.], including the requirements under sections 505(o), 505(p), and 505–1 of such Act [21 U.S.C. 355(o), (p), 355–1], applies to a biological product subject to regulation under this section, except that a product for which a license has been approved under subsection (a) shall not be required to have an approved application under section 505 of such Act.

(k) Licensure of biological products as biosimilar[struck: or interchangeable]

(1) In general Any person may submit an application for licensure of a biological product under this subsection.

(2) Content

(A) In general

(i) Required information An application submitted under this subsection shall include information demonstrating that—

[struck: (I)] [inserted: (i)] the biological product is biosimilar to a reference product based upon data derived from—

(I) [inserted: analytical studies that demonstrate that the biological product is highly similar to the reference product notwithstanding minor differences in clinically inactive components;]

(II) [inserted: an assessment of toxicity (which may rely on, or consist of, a study or studies described in item (aa) or (cc)); and]

(III) [inserted: a clinical study or studies (including the assessment of immunogenicity and pharmacokinetics or pharmacodynamics) that are sufficient to demonstrate safety, purity, and potency in 1 or more appropriate conditions of use for which the reference product is licensed and intended to be used and for which licensure is sought for the biological product;]

[struck: (aa)] [struck: analytical studies that demonstrate that the biological product is highly similar to the reference product notwithstanding minor differences in clinically inactive components;]

[struck: (bb)] [struck: an assessment of toxicity (which may rely on, or consist of, a study or studies described in item (aa) or (cc)); and]

[struck: (cc)] [struck: a clinical study or studies (including the assessment of immunogenicity and pharmacokinetics or pharmacodynamics) that are sufficient to demonstrate safety, purity, and potency in 1 or more appropriate conditions of use for which the reference product is licensed and intended to be used and for which licensure is sought for the biological product;]

[struck: (II)] [inserted: (ii)] the biological product and reference product utilize the same mechanism or mechanisms of action for the condition or conditions of use prescribed, recommended, or suggested in the proposed labeling, but only to the extent the mechanism or mechanisms of action are known for the reference product;

[struck: (III)] [inserted: (iii)] the condition or conditions of use prescribed, recommended, or suggested in the labeling proposed for the biological product have been previously approved for the reference product;

[struck: (IV)] [inserted: (iv)] the route of administration, the dosage form, and the strength of the biological product are the same as those of the reference product; and

[struck: (V)] [inserted: (v)] the facility in which the biological product is manufactured, processed, packed, or held meets standards designed to assure that the biological product continues to be safe, pure, and potent.

(ii) Determination by Secretary The Secretary may determine, in the Secretary’s discretion, that an element described in clause (i)(I) is unnecessary in an application submitted under this subsection.

(iii) Additional information An application submitted under this subsection—

(I) shall include publicly-available information regarding the Secretary’s previous determination that the reference product is safe, pure, and potent;

(II) may include any additional information in support of the application, including publicly-available information with respect to the reference product or another biological product; and

(III) may include information to show that the conditions of use prescribed, recommended, or suggested in the labeling proposed for the biological product have been previously approved for the reference product.

[struck: (B)] [struck: Interchangeability] [struck: An application (or a supplement to an application) submitted under this subsection may include information demonstrating that the biological product meets the standards described in paragraph (4).]

(3) Evaluation by Secretary Upon review of an application (or a supplement to an application) submitted under this subsection, the Secretary shall license the biological product under this subsection if—

(A) the Secretary determines that the information submitted in the application (or the supplement) is sufficient to show that the biological product—

(i) is biosimilar to the reference product; or

(ii) meets the standards described in paragraph (4), and therefore is interchangeable with the reference product; and

(B) the applicant (or other appropriate person) consents to the inspection of the facility that is the subject of the application, in accordance with subsection (c).

(4) [struck: Safety standards for determining interchangeability][inserted: Interchangeability.—] [struck: Upon review of an application submitted under this subsection or any supplement to such application, the Secretary shall determine the biological product to be interchangeable with the reference product if the Secretary determines that the information submitted in the application (or a supplement to such application) is sufficient to show that—]

(A) [inserted: In general.—] [inserted: A biological product licensed under this subsection shall be deemed to be interchangeable with the reference product, subject to subparagraph (B).]

[struck: the biological product—]

[struck: (i)] [struck: is biosimilar to the reference product; and]

[struck: (ii)] [struck: can be expected to produce the same clinical result as the reference product in any given patient; and]

(B) [inserted: Timing of deemed interchangeability.—]

(i) [inserted: Licensure on or after transition date.—] [inserted: A biological product licensed under this subsection on or after the transition date described in subparagraph (C) (referred to in this clause as the “applicable biological product”) shall be deemed to be interchangeable with the reference product upon such licensure, unless the applicable biological product relied on the same reference product as another biological product for which—]

(I) [inserted: licensure under this subsection was in effect on the day before the date of enactment of the Biosimilar Red Tape Elimination Act; and]

(II) [inserted: a first interchangeable exclusivity period under paragraph (6) (as in effect on the day before the date of enactment of the Biosimilar Red Tape Elimination Act) is in effect on the date of licensure of the applicable biological product,]

[inserted: in which case the applicable biological product shall be deemed interchangeable with the reference product under this paragraph on the date on which the exclusivity period described in subclause (II) ends.]

(ii) [inserted: Licensure prior to transition date.—] [inserted: A biological product licensed under this subsection prior to the transition date described in subparagraph (C) (referred to in this clause as the “applicable biological product”) shall be deemed to be interchangeable with the reference product on such transition date, unless the applicable biological product relied on the same reference product as another biological product for which—]

(I) [inserted: licensure under this subsection was in effect on the day before the date of enactment of the Biosimilar Red Tape Elimination Act; and]

(II) [inserted: a first interchangeable exclusivity period under paragraph (6) (as in effect on the day before the date of enactment of the Biosimilar Red Tape Elimination Act) is in effect on the transition date,]

[inserted: in which case the applicable biological product shall be deemed interchangeable with the reference product under this paragraph on the date on which the exclusivity period described in subclause (II) ends.]

(C) [inserted: Transition date.—] [inserted: The transition date described in this subparagraph is the date that is 60 days after the date of enactment of the Biosimilar Red Tape Elimination Act.]

[struck: for a biological product that is administered more than once to an individual, the risk in terms of safety or diminished efficacy of alternating or switching between use of the biological product and the reference product is not greater than the risk of using the reference product without such alternation or switch.]

(5) General rules

(A) One reference product per application A biological product, in an application submitted under this subsection, may not be evaluated against more than 1 reference product.

(B) Review An application submitted under this subsection shall be reviewed by the division within the Food and Drug Administration that is responsible for the review and approval of the application under which the reference product is licensed.

(C) Risk evaluation and mitigation strategies The authority of the Secretary with respect to risk evaluation and mitigation strategies under the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 301 et seq.] shall apply to biological products licensed under this subsection in the same manner as such authority applies to biological products licensed under subsection (a).

(6) [struck: Exclusivity][inserted: Transition] [struck: for][inserted: with] [inserted: respect to preserving ]first interchangeable [inserted: exclusivity with respect to certain ]biological [struck: product][inserted: products.—] [inserted: With respect to a biological product licensed under this subsection before the date of enactment of the Biosimilar Red Tape Elimination Act, for which there was an unexpired period of first interchangeable exclusivity under this subsection (as then in effect), such unexpired exclusivity period shall remain in effect for the duration of such period.]

[struck: The Secretary shall not make approval as an interchangeable biological product effective with respect to an application submitted under this subsection that relies on the same reference product for which a prior biological product has received a determination of interchangeability for any condition of use, until the earlier of—]

[struck: (A)] [struck: 1 year after the first commercial marketing of the first interchangeable biosimilar biological product to be approved as interchangeable for that reference product;]

[struck: (B)] [struck: 18 months after—]

[struck: (i)] [struck: a final court decision on all patents in suit in an action instituted under subsection (l)(6) against the applicant that submitted the application for the first approved interchangeable biosimilar biological product; or]

[struck: (ii)] [struck: the dismissal with or without prejudice of an action instituted under subsection (l)(6) against the applicant that submitted the application for the first approved interchangeable biosimilar biological product; or]

[struck: (C)]

[struck: (i)] [struck: 42 months after approval of the first interchangeable biosimilar biological product if the applicant that submitted such application has been sued under subsection (l)(6) and such litigation is still ongoing within such 42-month period; or]

[struck: (ii)] [struck: 18 months after approval of the first interchangeable biosimilar biological product if the applicant that submitted such application has not been sued under subsection (l)(6).]

[struck: For purposes of this paragraph, the term “final court decision” means a final decision of a court from which no appeal (other than a petition to the United States Supreme Court for a writ of certiorari) has been or can be taken, and the term “first interchangeable biosimilar biological product” means any interchangeable biosimilar biological product that is approved on the first day on which such a product is approved as interchangeable with the reference product.]

(7) Exclusivity for reference product

(A) Effective date of biosimilar application approval Approval of an application under this subsection may not be made effective by the Secretary until the date that is 12 years after the date on which the reference product was first licensed under subsection (a).

§ 262(k)(8)Guidance documents(D)–(E)

(k)(7)(B)–(8)(C) unchanged ·

(D) Requirement for product class-specific guidance If the Secretary issues product class-specific guidance under subparagraph (A), such guidance shall include a description of—

(i) the criteria that the Secretary will use to determine whether a biological product is highly similar to a reference product in such product class[struck: ; and][inserted: .]

[struck: (ii)] [struck: the criteria, if available, that the Secretary will use to determine whether a biological product meets the standards described in paragraph (4).]

(E) Certain product classes

(i) Guidance The Secretary may indicate in a guidance document that the science and experience, as of the date of such guidance, with respect to a product or product class (not including any recombinant protein) does not allow approval of an application for a license as provided under this subsection for such product or product class.

Rest of § 262 unchanged ·

42 U.S.C. § 263–1 Education on biological products

+5 −5Shown
More for 42 U.S.C. § 263–1
Read § 263–1Only this section
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Section 352A of the Public Health Service Act (42 U.S.C. 263–1) is amended by striking and interchangeable biosimilar biological products each place it appears.

§ 263–1(a)

§ 263–1. Education on biological products

(a) Internet website

(1) In general The Secretary may maintain and operate an internet website to provide educational materials for health care providers, patients, and caregivers, regarding the meaning of the terms, and the standards for review and licensing of, biological products, including biosimilar biological products [struck: and interchangeable biosimilar biological products].

(2) Content Educational materials provided under paragraph (1) may include—

(A) explanations of key statutory and regulatory terms, including “biosimilar” and “interchangeable”, and clarification regarding the use of interchangeable biosimilar biological products;

(B) information related to development programs for biological products, including biosimilar biological products and [struck: interchangeable biosimilar biological products and ]relevant clinical considerations for prescribers, which may include, as appropriate and applicable, information related to the comparability of such biological products;

(C) an explanation of the process for reporting adverse events for biological products, including biosimilar biological products [struck: and interchangeable biosimilar biological products]; and

(D) an explanation of the relationship between biosimilar biological products [struck: and interchangeable biosimilar biological products ]licensed under section 262(k) of this title and reference products (as defined in section 262(i) of this title), including the standards for review and licensing of each such type of biological product.

(3) Format The educational materials provided under paragraph (1) may be—

(A) in formats such as webinars, continuing education modules, videos, fact sheets, infographics, stakeholder toolkits, or other formats as appropriate and applicable; and

§ 263–1(a)–(b)

(a)(3)(B)–(4)(B) unchanged ·

(5) Confidential and trade secret information This subsection does not authorize the disclosure of any trade secret, confidential commercial or financial information, or other matter described in section 552(b) of title 5.

(b) Continuing education The Secretary shall advance education and awareness among health care providers regarding biological products, including biosimilar biological products [struck: and interchangeable biosimilar biological products], as appropriate, including by developing or improving continuing education programs that advance the education of such providers on the prescribing of, and relevant clinical considerations with respect to, biological products, including biosimilar biological products [struck: and interchangeable biosimilar biological products].

21 U.S.C. § 355c Research into pediatric uses for drugs and biological products

Couldn't place the change
More for 21 U.S.C. § 355c
Read § 355cOnly this section

The bill's words for this section

  1. Not carried out:

    Section 505B(l) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355c(l)) to read as follows:(l) Biosimilar biological products.— A biological product for which an application is submitted under section 351(k) of the Public Health Service Act shall not be considered to have a new active ingredient for purposes of this section, unless the application seeks licensure for— …

    We can't read how this instruction is worded yet, so it isn't shown in the text.

    Technical detailno-pattern: to read as follows: QCONTENT.

21 U.S.C. § 379j–51 Definitions

Couldn't place the change
More for 21 U.S.C. § 379j–51
Read § 379j–51Only this section

The bill's words for this section

  1. Not carried out:

    Section 744G(14) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379j–51(14)) is amended by striking , including a supplement requesting that the Secretary determine that the biosimilar biological product meets the standards for interchangeability described in section 351(k)(4) of the Public Health Service Act.

    “, including a supplement requesting that the Secretary determine that the biosimilar biological product meets the standards for interchangeability described in section 351(k)(4) of the Public Health Service Act” isn't in § 379j–51(14) in the Code as we have it. The law may have changed since the bill was drafted.

    Technical detail“, including a supplement requesting that the Secretary determine that the biosimilar biological product meets the standards for interchangeability described in section 351(k)(4) of the Public Health Service Act” not found in /us/usc/t21/s379j–51/14

Step through the changes